The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.
The coenzyme nicotinamide adenine dinucleotide (NADH) has been used in an open label trial as novel medication in 34 patients with Parkinson's disease, using an intravenous administration technique. In all patients a beneficial clinical effect was observed. 21 patients (61.7%) showed a very good (better than 30%) improvement of disability, 13 patients (38.3%) a moderate (up to 30%) improvement. Concomitant with the improvement of the disability the urine level of homovanillic acid (HVA) increased significantly in all patients (in some patients by more than a 100%). The daily "on phases" of the patients could be increased from 2 up to 9 hours in the individual patients by NADH administration.
Birkmayer
W
W
Birkmayer-Institut für Parkinsontherapie, Vienna, Austria.
Birkmayer
G J
GJ
Vrecko
K
K
Mlekusch
W
W
Paletta
B
B
Ott
E
E
D000368:Aged; D000369:Aged, 80 and over; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D009243:NAD / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology
D009243:NAD; D006719:Homovanillic Acid